Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.

Neurodegenerative disease management2026PMID: 42159155

View on PubMed DOI: 10.1080/17582024.2026.2666332

Authors

Cummings, Jeffrey L; Atri, Alireza; Sano, Mary; Zetterberg, Henrik; Scheltens, Philip; Knop, Filip K; Johannsen, Peter; Wichmann, Christian A; Abschneider, Rikke Mortensen; Leon, Teresa; Taylor, Jim; Feldman, Howard H

Keywords

Alzheimer’s diseasecognitive functionearly-stage ADevokeevoke(+)evoke+glucagon-like peptide-1 receptor agonistphase 3 trialsemaglutidesmall vessel pathology